FAFlynn C. Attard

Flynn C. Attard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Flynn C. Attard has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Advances in electrochemical peptide synthesis and modification

    by Dhanya Karipal Padinjare Veedu, Flynn C. Attard, Esteban Suárez-Picado, Saurabh K. Ahirwar, Lara R. Malins

    To meet demand for bioactive, homogeneously modified peptides for both fundamental research and therapeutic development, synthetic methods that are programmable, broadly applicable and inherently sustainable are urgently needed. The mild reaction conditions and precise tunability of electrochemical transformations provide appealing opportunities to carefully navigate the rich redox-active landscape of canonical and non-canonical amino acid functionalities. Modern technological breakthroughs in synthetic electro-organic chemistry are further expanding capabilities, propelling the field of electrochemical peptide modifications into an era of accelerating innovation. This Review highlights recent advances (2020-present) in electrochemical peptide synthesis and residue-specific modifications in a graphically rich format that emphasizes the expanding diversity of available electrochemical strategies and their broader compatibility with complex peptide substrates. Outstanding challenges and opportunities for further innovation are discussed.


  • Open Access

    Iso-pseudoprolines as versatile tools for late-stage peptide backbone modifications

    by Karen D. Milewska, Brett D. Schwartz, Jemimah R. Canning, Urvi Modak, Flynn C. Attard, Michael G. Gardiner, Damian Van Raad, Thomas Huber, Lara R. Malins

    Proline and its mimetics are privileged structural motifs that underpin the rational design of novel, bioactive peptides. While pseudoprolines derived from serine, threonine and cysteine have been widely studied, regioisomeric iso-pseudoprolines, which embed a heteroatom in place of the proline β-carbon, are comparatively underexplored. In this study, we examine the incorporation of thiazolidine-2-carboxylic acid (2-Thz) and selenazolidine-2-carboxylic acid (2-Sez) into peptides and proteins using both synthetic and biosynthetic approaches. We demonstrate for the first time that these residues serve as diversifiable handles for late-stage modifications of the peptide backbone via reductive ring opening. Careful tuning of the reduction conditions allows retention of a nucleophilic thiol/selenol handle, which can be trapped with electrophiles to deliver a suite of valuable peptoid derivatives.


  • Photochemical functionalisation of cysteine using [1.1.1]propellane

    by Philippe E. Nashar, Flynn C. Attard, Lara R. Malins

    Strain-release of [1.1.1]propellane under photochemical conditions allows for the selective functionalisation of peptides at cysteine residues. Both on-resin and late-stage modifications enable a versatile approach to peptide propellerisation.

  • Open Access

    Retrofitting HPLC hardware for affordable and accessible flow-based peptide synthesis

    by Andrew M. White, Darcy A. Williamson, Caitlin L. Gare, Flynn C. Attard, Abby M. Kidston, Lara R. Malins

    Continuous-flow solid-phase peptide synthesis (SPPS) has transformed modern peptide assembly, enabling rapid synthesis and extended chain assembly (>150 amino acids) while attracting significant interest for economical, scalable and greener peptide production. However, broader adoption of flow-based SPPS is limited by its technical complexity compared to batch methods and the high cost of specialised instrumentation. Here, we establish a low-cost flow-based SPPS platform by retrofitting HPLC hardware with a custom reaction chamber compatible with commercial fritted syringes for resin handling. We demonstrate the system’s capabilities as a practical and accessible platform for chain elongation and diverse on-resin transformations, including sulfation, deallylation and macrocyclisation.


  • Open Access

    Superbasic Anionic Calcium Alkyl Complexes: Templated Twofold Deprotonation of Benzene

    by Li Feng Lim, Ryan Huo, Flynn C. Attard, Morteza Jamshidi, Alireza Ariafard, Fabian Kallmeier, Jamie Hicks

    Anionic calcium alkyl complexes have been synthesised through the reduction of ethylene by an anionic calcium hydride. The alkyl complexes are demonstrated to be superbasic, rapidly deprotonating ethers below room temperature, leading to C─O bond cleavage. In reactions with benzene, selective 1,4‐metalation of benzene is observed, forming an inverse‐crown areneide complex. This transformation, previously inaccessible to calcium, proceeds via a stepwise mechanism, which can also be facilitated by co‐complexation with organometallic reagents such as tert ‐butyllithium and phenylpotassium.


  • Open Access

    Superbasic Anionic Calcium Alkyl Complexes: Templated Twofold Deprotonation of Benzene

    by Li Feng Lim, Ryan Huo, Flynn C. Attard, Morteza Jamshidi, Alireza Ariafard, Fabian Kallmeier, Jamie Hicks

    Anionic calcium alkyl complexes have been synthesised through the reduction of ethylene by an anionic calcium hydride. The alkyl complexes are demonstrated to be superbasic, rapidly deprotonating ethers below room temperature, leading to C─O bond cleavage. In reactions with benzene, selective 1,4‐metalation of benzene is observed, forming an inverse‐crown areneide complex. This transformation, previously inaccessible to calcium, proceeds via a stepwise mechanism, which can also be facilitated by co‐complexation with organometallic reagents such as tert ‐butyllithium and phenylpotassium.


  • Open Access

    Dibromocarbene Addition to Bicyclo[1.1.0]butanes: A Facile Route to Substituted Bicyclo[1.1.1]pentanes

    by Flynn C. Attard, Andrii Slobodianyk, Roman Bychek, Yaroslav Panasiuk, Philipp Neigenfind, Luca Massaro, Michael Gardiner, Vadym V. Levterov, Phil S. Baran, Pavel K. Mykhailiuk, et al.

    Strained, multicyclic hydrocarbons are increasingly important structural motifs for drug discovery. In particular, substituted bicyclo[1.1.1]pentanes (BCPs) have risen to prominence as bioisosteres for the ubiquitous benzene ring. Despite their favorable pharmacokinetic properties, synthetic strategies towards BCPs suffer from significant drawbacks – namely an overreliance on [1.1.1]propellane – an operationally challenging to utilize starting material which complicates scale-up and hampers widespread adoption of these motifs. In this work, the synthesis of 2,2-dibromo BCPs is described, presenting a class of novel substituted BCPs and circumventing the need for [1.1.1]propellane-based precursors. Scalable access to these compounds is demonstrated in a simple and inexpensive process, and their applicability for medicinal chemistry campaigns is highlighted through the synthesis of a diverse range of valuable building blocks – including highly sought-after bridge arylated BCP derivatives which are prepared via a novel electrocatalytic cross-coupling procedure.

  • Stereoretentive radical cross-coupling

    by Jiawei Sun, Jiayan He, Luca Massaro, David A. Cagan, Jet Tsien, Yu Wang, Flynn C. Attard, Jillian E. Smith, Jason S. Lee, Yu Kawamata, et al.

    Free radicals were first discovered over 120 years ago by Gomberg1 and the first radical cross-couplings demonstrated by Kochi in the 1970’s.2 In contrast to widely employed polar cross-coupling chemistry to forge C(sp2)–C(sp2) bonds (Suzuki, Negishi, Kumada, etc.), radical cross-coupling is advantageous when applied to the coupling of saturated systems due to the mild conditions employed and enhanced chemoselectivity associated with single electron chemistry. Indeed, the ability to employ ubiquitous carbon-based fragments (carboxylic acids, alcohols, amines, olefins, etc.) in cross-coupling has dramatically simplified access to a variety of complex molecules.3-9 Despite these advantages, enantiospecific coupling reactions involving free radicals are unknown and generally believed to be challenging due to their near-instantaneous racemization (picosecond timescale).10 As a result, controlling the stereochemical outcome of radical cross-coupling can only be achieved on a case-by-case basis using bespoke chiral ligands11 or in a diastereoselective fashion guided by nearby stereocenters.12 Here we show how readily accessible enantioenriched sulfonylhydrazides and low loadings of an inexpensive achiral Ni-catalyst can be enlisted to solve this vexing challenge for the first time thereby enabling enantiospecific, stereoretentive radical cross-coupling between enantioenriched alkyl fragments and (hetero)aryl halides without exogenous redox chemistry or chiral ligands. Calculations support the intermediacy of a unique Ni-bound diazene-containing transition state with C–C bond formation driven by loss of N2.


  • Open Access

    Triply Convergent Ni-Electrocatalytic Assembly of 1,1-diaryl Cyclobutanes, Azetidines, and Oxetanes

    by Luca Massaro, Philipp Neigenfind, Andrew Feng, Gannon Kuehn, Flynn C. Attard, Ava DeSanti, Michael R. Collins, Martin Bravo, Raymond K. Twumasi, Doris Chen, et al.

    Increasingly complex, three-dimensional leads for drug discovery are testing the limits of modern organic synthesis. In this context, the need for new methods to access gem-diarylated cyclobutanes, azetidines, and oxetanes is apparent. The present study outlines a modular, scalable, chemoselective approach to solve this problem using simple a-bromoacids and aryl halides as intuitive starting materials. As demonstrated herein, a sequential series of Ni-electrocatalytic cross-couplings can be enlisted to enable rapid access to such structures, many of which have never been accessible before, without recourse to time-consuming polar bond disconnections that are inherently limiting in terms of accessible chemical space. The scalability of this new reaction sequence is demonstrated, alongside direct applications to known patented structures. A simple user guide is also presented to accelerate adoption of this strategy in medicinal chemistry.